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Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects
synovial joints. Validated laboratory parameters for RA diagnosis are higher blood levels
of rheumatoid factor IgM (IgM-RF), anti-citrullinated protein autoantibodies (ACPA),
C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR). Clinical
parameters used are the number of tender (TJC) and swollen joints (SJC) and the
global patient visual analog score (VAS). To determine disease remission in patients a
disease activity score (DAS28) can be calculated based on SJC, TJC, VAS, and ESR
(or alternatively CRP). However, subtle and better predictive changes to follow treatment
responses in individual patients cannot bemeasured by the abovementioned parameters
nor by measuring cytokine levels in blood. As extracellular vesicles (EVs) play a role in
intercellular communication and carry a multitude of signals we set out to determine their
value as a biomarker for disease activity. EVs were isolated from platelet-free plasma
of 41 RA patients and 24 healthy controls (HC) by size exclusion chromatography
(SEC). We quantified the particle and protein concentration, using NanoSight particle
tracking analysis and micro-BCA, respectively, and observed no differences between
RA patients and HC. In plasma of 28 out of 41 RA patients IgM-RF was detectable by
ELISA, and in 13 out of these 28 seropositive RA patients (RF+RA) IgM-RF was also
detected on their isolated pEVs (IgM-RF+). In seronegative RA patients (RF−RA) we
did not find any RF present on pEVs. When comparing disease parameters we found
no differences between RF+RA and RF−RA patients, except for increased ESR levels
in RF+RA patients. However, RF+RA patients with IgM-RF+ pEVs showed significantly
higher levels of CRP and ESR and also VAS and DAS28 were significantly increased
compared to RA+ patients without IgM-RF+ pEVs. This study shows for the first time
the presence of IgM-RF on pEVs in a proportion of RF+RA patients with a higher disease
activity.
Keywords: rheumatoid arthritis, rheumatoid factor IgM, extracellular vesicles, disease activity score 28, C-reactive
protein, ESR, plasma
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INTRODUCTION
Rheumatoid arthritis is an autoimmune disease in which the
body’s immune system mistakenly attacks the synovial joints
leading to joint inflammation as a hallmark feature of this disease
(1). The diagnosis of RA relies on physical examination and
laboratory blood testing. Rheumatoid factor (RF) is found in 50%
of early RA patients rising to 90% at advanced stages of disease
(2). Seropositive RA patients (RF+RA) have detectable RF in
their circulation and it has been shown that high RF levels are
predictors of more severe disease forms (3). The pathogenesis
of RA may be different between RF+RA and RF−RA patients
with the later often reported as less severe although studies are
conflicting (4). RF contribute to the disease process of RA by
a mechanism where large immune complexes are formed and
complement activation is induced (5). Cardiovascular disease
and organ involvement such as the lungs, heart, and eyes are well-
recognized complications occurring primarily in RF+RA patients
(6).
To determine the disease activity in all RA patients a formula
has been developed (DAS28) by our department that includes the
physical examination of 28 joints for tenderness and swelling,
the erythrocyte sedimentation rate (or C-reactive protein levels
instead) and a patient global visual analog score (of pain or
global health) (7). DAS28 is a good tool to define remission
in established RA but has limited value in monitoring disease
processes and responses. It is well-recognized that numerous
cytokines play an important role in the local and systemic
inflammatory response in RA and although targeting these
cytokines using biological is therapeutically successful in many
RA patients their usefulness as biomarkers to monitor disease
activity and treatment response is poor, even a combination of 12
cytokines in the multi-biomarker disease activity (MBDA) score
has limited predictive value (8). Until now, most research on
rheumatoid arthritis has focused on cytokines as main effectors
in disease progression however, cell-cell communication involves
a much broader scope of responses including proliferation,
apoptosis and migration. In terms of communication a cell can
release additionally extracellular vesicles (EVs) and recently an
important role of these EVs has been postulated as important
communicators between resident and inflammatory cells (9).
EVs play a regulatory role in immunity during health
and disease (10, 11) and are suggested to be involved in
auto-immune disease (12). They are released from cells and
are detectable in body fluids such as blood, synovial fluid,
urine and breast milk (13). They contain numerous proteins
(including cytokines), lipids (prostaglandins), RNA, DNA, and
sometimes even cell organelles such as mitochondria (14).
Three subtypes of EVs have been described: apoptotic bodies
(1–10 µm), microvesicles (100–1000 nm), and exosomes (30–
100 nm), which are classified based on their origin, programmed
cell disintegration, plasma membrane outward budding, and
release via multivesicular bodies, respectively (15). Interestingly,
specific membrane proteins are enriched in exosomes in a cell-
type dependent fashion (13, 16). Additionally, preliminary data
suggest that exosome content differs between individual people.
This enrichment of specific proteins in exosomes compared to
those that are found in the cytoplasm of the donor cell could
mean these vesicles play some distinctive function (16).
It is known that B-cells also release EVs that contain the B-cell
receptor on their surface which is an immunoglobulin that binds
and presents antigens to T-cells (17). The presence of IgM-RF in
RF+RA patients clearly points to a role of B-cells and plasma cells
in the pathogenesis of this disease (18). A B-cell depleting strategy
by a monoclonal anti-CD20 antibody (Rituximab) is a highly
effective therapy in RA patients (19). Therefore, we investigated
the presence of IgM-RF on EVs and its relation to the activity of
RA determined by laboratory and clinical parameters.
METHODS
Blood Donors
Blood was obtained from 41 RA patients fulfilling ACR/EULAR
classification (20), of which 28 patients had a IgM-RF titer >
10 IU/ml (RF+RA). Tender (TJC) and swollen joints (SJC) were
assessed by physicians and the global patient visual analog score
(VAS) was determined by the patient, where a point was set on a
100mm line as a reflexion of their disease feeling after which the
distance to the point was measured (0 = no disease, 100 = worst
disease feeling).
ESR and CRP levels were determined by standard laboratory
blood tests in our hospital. Disease activity score (DAS28) was
calculated based on SJC, TJC, VAS, and ESR. An overview of the
rheumatic arthritis disease status and medication of RF+RA and
RF−RA patients are shown in Table 1. As age matched controls,
blood from healthy controls (HC) were obtained from the blood
transfusion department (Sanquin, Nijmegen, The Netherlands).
All donors provided informed consent under institutional ethics
committee approved protocols.
Blood Sample Preparation
Blood samples were taken in ethylenediaminetetraacetic acid
tubes (BD, Plymouth, UK) and within 1 h centrifuged for 10min
at 1690 g by 4◦C to obtain plasma. Plasma was centrifuged at
10,000 g for 30min by 4◦C to obtain platelet free plasma (pfp).
Thereafter the supernatant was passed through a 0.22µm filter
(Whatmann) and aliquoted. Aliquots were stored at−80◦C until
EV isolation.
Plasma EV Isolation
pEVs were isolated by size exclusion chromatography (SEC)
using the protocol described by Lobb et al. (21). In short, a sterile
column was prepared for SEC using a 10ml syringe stacked with
sepharose CL-2B (Pharmacia, Uppsala, Sweden). After washing
the column with phosphate buffered saline (PBS) containing
0.32% citrate (pH 7.4, autoclaved), 0.5ml of pfp was loaded and
eluted using PBS/0.32% citrate buffer. 1ml eluate fractions were
collected and fraction 5 containing the EVs was stored at 4◦C for
further use.
Protein Measurement
The amount of protein was measured using aMicro BCA Protein
assay kit following the protocol provided by the manufacturer
(Thermoscientific, Rockford, USA). pEV samples were diluted
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TABLE 1 | Clinical characteristics of RA patients at time of blood collection.
Rheumatoid arthritis disease status
RF−RA (n = 13) RF+RA (n = 28)
Mean Count Mean Count P-value
Age in years 57 [39–75] 61 [26–85] 0.256
Gender male 4 (30.8%) 6 (21.4%)
female 9 (69.2%) 22 (78.6%)
DAS-28 score 3.33 [1.53–5.56] 4.13 [1.60–6.53] 0.101
IgM-RF - 13 (100%) -
+ - 28 (100%)
ESR (mm/hr) 15.5 [2–44] 30.6 [2–104] 0.016
CRP (mg/l) 9.8 [1–58] 15.4 [7–76] 0.140
VAS 55.3 [0–78] 46.7 [0–100] 0.194
TJC 2.6 [0–8] 4.8 [0–22] 0.075
SJC 2.2 [0–10] 4.1 [0–16] 0.051
DMARDs use 11 (84.6%) 20 (71.4%)
Solumedrol use 4 (30.8%) 18 (64.3%)
Analgesics use 10 (76.0%) 22 (78.6%)
Biological use 2 (15.4%) 6 (21.4%)
10, 20, 40, and 80 times in NaCl 0.9% and after 2 h incubation
at 37◦C absorbance was measured using the BioRad iMark
microplate reader.
Nanoparticle Tracking Analysis
Vesicle size distribution was estimated by the Brownian motion
of particles using a NanoSight NS300 (Sysmex, Etten-Leur, The
Netherlands) with Nanoparticle Tracking Analysis 3.2 software
(NanoSight, Amesbury, UK). Vesicles were diluted in PBS, till
an optimal concentration for reliable analysis was reached (20–
80 particles per frame). Each sample was measured for 60 s (in
duplicates), using the following software settings: flow rate 50,
camera level 10 and detection threshold 5.
Transmission Electron Microscopy
Fraction 5 of SEC was washed using Vivaspin-2 columns
(Sartorius Stedim Biotech GmbH, Goettingen, Germany) to
remove salts from the solution and 3 µl EVs in deionized
water was placed on a nickel grid and allowed to dry to air for
45min. The grids were then washed by transferring them onto
several drops of deionized water. Negative contrast staining was
performed by incubating the grids on top of drops of 6% uranyl
acetate. Excess fluid was removed and the grids were allowed
to dry before examination in a JEM1200 transmission electron
microscope (Jeol, The Netherlands).
Sucrose Gradient
The density of isolated pEVs was determined by sucrose gradient
described by Chiou (22). In short, 100 µl SEC isolated pEVs
was mixed with 1ml 70% sucrose (Sigma). Thereafter, a sucrose
gradient was layered on top of the 70% in a centrifuge tube (14
× 19mm; Beckman Instruments Inc. USA) and spun for 18 h in
a SW 40 Ti rotor (100,000 g at 4◦C). After centrifugation, 1ml
fractions were taken and washed with PBS. Finally, EVs were
pelleted at 166,000 g for 90min and were taken up in 100 ul PBS.
Particle concentration was measured by NTA.
IgM-RF Detection
IgM-RF was detected by ELISA. In short, in a 96 wells plate
aggregated human IgG (Sigma) was coated. After washing, pEVs
were added and incubated for 90min. Wells were washed twice,
thereafter HRP-labeled Goat-anti-IgM F(ab’)2 fragment (BioMP)
was added and incubated for 90min. Following a third washing
step TMB was added to bind HRP. By addition of acid, the
enzyme reaction was stopped and plate was measured at 450 nm.
IgM levels were calculated using a standard curve. RA patients
with an IgM-RF titer> 10 IU/ml in plasma were scored as RF+ at
the clinical lab. For pEVs IgM-RF levels> 2 IU/ml were regarded
as IgM-RF+ pEVs in our study.
Detection of Labeled pEVs Bound to
Protein L Beads
Based on the protocol previously described (23) pEVs were
diluted in PBS before addition of 300 µl of Diluent C and 1
µl PKH-26 (Sigma). The samples were gently mixed for 2min
before adding 500 µl 1% BSA to stop the membrane staining
and were loaded onto 300 kDa Vivaspin filters (Sartorius Stedim
Biotech GmbH, Goettingen, Germany). After centrifuged at
4,000 g samples were washed three times with 2ml PBS and taken
up in 500 µl PBS. Labeled pEVs were bound to immobilized
Protein L magnetic beads (Thermoscientific, Rockford, USA).
After short incubation in a magnet the unbound pEVs were
collected. After washing three times with PBS + 0.1%BSA pEVs
bound to Protein L magnetic beads were collected. Fluorescence
of Protein-L bound and unbound pEVs was measured on a
fluorometer (Clariostar, BMG).
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Detection of IgG Binding to pEVs
IgG binding to IgM-RF+ pEVs and protein-L unbound IgM-
RF+pEVs was measured by bead-assisted flowcytometry (FC).
pEVs were coupled to antiCD63 magnetic beads (Thermo Fisher
Scientific) for 3 h at RT. Unbound pEVs were removed by 3
washing steps. Thereafter CD63+ pEVs were incubated with IgG-
PE (eBioscience) for 1 h and after 3 washing steps coupled IgG-PE
was measured by FC.
Statistical Analysis
All data are expressed as mean ± SD. Data were compared
using two tailed Mann-Whitney U-test. Values of P < 0.05 were
considered to indicate statistical significance. Correlations were
represented by the Pearson correlation coefficient (r) and their
p-value. All statistical analyses were performed using GraphPad
Prism 5.01 (GraphPad Software, La Jolla, CA).
RESULTS
Characterization of pEVs
To separate EVs from plasma proteins SEC isolation was used as
described before (21). Collection of eluent showed that fraction
5 displayed the highest particle concentration (detected by NTA)
while in fractions 6 and above high protein levels were detected
(measured by BCA measurement) (Figure 1A). The particle size
of SEC eluted fraction 5 was around 100 nm as determined by
NTA (Figure 1B), in line with the observed size visualized by
TEM (Figure 1C). For all further studies SEC eluent fraction 5
was used. The main density of the isolated pEVs was 1.17 g/ml
(sucrose density) (Figure 1D), which confirmed the presence of
exosomes.
Comparison of pEVs From RA Patients and
Healthy Subjects
When comparing pEVs isolated from RA patients and HC, we
observed no differences in particle size (Figure 2A), protein
content (Figure 2B) and particle concentration (Figure 2C)
(115 nm, 49fg, 3.5 × 1010 and 108 nm, 45fg, 3.8 × 1010,
respectively). In addition, between RF−RA and RF+RA patients,
particle size (Figure 2D), protein content per particle (Figure 2E)
and amount of particles (Figure 2F) of pEVs were not statistically
different (116 nm, 39fg, 5.41010 and 114 nm, 58fg, 1.8 × 1010,
respectively). The RF−RA and RF+RA patient groups did not
statistically differ in terms of demographics (Table 1), clinical
parameters (DAS28, VAS, TJC and SJC) and CRP (Figures 3A–E,
respectively) except for the erythrocyte sedimentation rate
(Figure 3F) which was higher in the RF+RA group.
Detecting RF on pEVs in RA Patients
To investigate whether IgM-RF, as detected in plasma of RF+RA
patients by ELISA, could also be detected in fraction 5 of
the SEC isolated pEVs, IgM-RF ELISA was performed and in
FIGURE 1 | pEV isolation by SEC. Platelet free plasma components were separated by size exclusion chromatography (SEC). For each 1ml fraction, protein and
particle concentrations were measured by micro-BCA protein assay and Nanosight tracking analysis (NTA) (A). Particle size from SEC fraction 5 was analyzed by NTA
(B) and TEM (C). Density of pEVs was determined by use of a sucrose gradient and particles of each density fraction were measured by NTA (D).
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FIGURE 2 | Characterization of pEVs from healthy controls and RA patients. Mode particle size (A), protein content per particle (B), and amount of particles (C) from
pEVs isolated from 500 µl pfp of HC (n = 24) or RA patients (n = 41) were measured by NTA and micro-BCA protein assay. Next, RA patients were divided in 2
groups based on the presence of IgM-RF (RF+RA; n = 28 and RF−RA; n = 13). Particle size (D), protein per particle (E) and amount of particles (F) of isolated pEVs
are shown measured by NTA and micro-BCA protein assay.
46% (13 out of 28 RF+RA patients) IgM-RF was detectable
(Figure 4A) while no IgM-RF was found in SEC eluent fraction
5 of RF−RA patients (data not shown). IgM-RF levels in pfp
were significantly enhanced in RF+RA patients with IgM-RF+
pEVs, although a high variability was observed in this group
(Figure 4B). This high variability and the result that levels of
IgM-RF as determined in SEC fraction 5 did not correlate
with the plasma levels of IgM-RF (Figure 4C) excludes the co-
isolation of plasma RF protein in SEC fraction 5. No differences
in particle size, particle concentration and protein concentration
per particle were observed between RF+RA patients with or
without IgM-RF on their pEVs (Figures 4D–F respectively).
Confirming the Presence of IgM-RF on
pEVs
RF are autoantibodies directed against the Fc-tail of
immunoglobulin G. To study the IgG binding to IgM-RF+
pEVs, we coupled pEVs isolated from 8 RF+RA patients
to anti-CD63 beads, incubated them with Phycoerythrin
(PE)-conjugated IgG and analyzed IgG binding using FC.
IgG-PE was bound to pEVs in the same RF+RA patients in
which IgM-RF was detected on EVs by ELISA (Figure 5A). A
representative FC plot of an RA patient with IgM-RF+ pEVs
is shown (Figure 5B). To investigate the amount of IgM-RF+
pEVs in the total isolated pEVs, pEVs were labeled with the
fluorescent membrane staining PKH26, thereafter incubated
with protein-L beads. Fluorescence was measured in the
protein-L bound- and unbound fractions. On average 3,6% more
fluorescence signal was detected in the protein-L bound fraction
of the IgM-RF+ pEVs compared with the IgM-RF− pEVs
(Figure 5C). Detection of IgG binding to protein-L unbound
pEVs showed a decreased PE signal indicating the presence
of IgM-RF on the pEVs (Figure 5D). These two different
approaches confirmed that the IgM-RF+ particles are actually
EVs because they have a lipid bilayer and carry the exosome
marker CD63.
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FIGURE 3 | Clinical parameters related to the presence of IgM-RF in blood. Based on the presence of IgM-RF in blood the RA patients were divided 2 groups,
RF+RA and RF−RA patients. Clinical parameters were obtained at time of blood donation. DAS28 (A), VAS disease activity (B), TJC (C), and SJC (D), and CRP and
ESR levels (E,F) of RF+RA and RF−RA patients are shown. Statistically significant differences were determined by Mann-Whitney test, *p < 0.05.
RF+RA Patients With IgM-RF Containing
pEVs Showed More Severe Disease
An overview of clinical data obtained from RF+RA patients
stratified in two groups based on presence of IgM-RF on their
pEVs is shown in Table 2. As IgM-RF and EVs are thought to
be implicated in the disease process, we divided the RF+RA
patients in 2 subgroups based on the presence or absence of
IgM-RF on their pEVs (IgM-RF+ pEVs and IgM-RF− pEVs).
After analyzing the coupling of the obtained clinical parameters
to these two subgroups we observed no differences on TJC and
SJC (Figures 6A,B). However DAS28, VAS disease activity, CRP
and ESR levels were significantly enhanced in patients with IgM-
RF+ pEVs (Figures 6C–F, respectively), suggesting the presence
of IgM-RF on pEVs to be a novel biomarker for disease activity
in RA patients.
DISCUSSION
In this study plasma EVs isolated from healthy controls an RA
patients did not show different characteristics in all parameters
studied, however in seropositive RA patients we have identified
a subgroup expressing IgM-RF on their pEVs and these patients
showing significantly higher disease activity.
We set out to study the putative differences between EVs from
RA patients and healthy controls as well as between serological
different RA patient groups. Others found that the number of
circulating EVs is enhanced in RA patients (24) but we could not
confirm this result in our study. The total particle concentration
of pEVs obtained was not different between RA patients and
HC. We also showed that the protein content and particle size
of pEVs isolated from RA patients were comparable to HC
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FIGURE 4 | IgM-RF detection in fraction 5 of SEC separated platelet free plasma. IgM-RF levels on pEVs isolated from all 28 RF+RA patients were measured by
ELISA and percentage of RF+RA patients with or without IgM-RF+ pEVs are shown (A). From these 2 subdivided groups IgM-RF blood levels are shown individually
per patient (B). Correlation of IgM-RF levels on pEVs and levels in platelet free plasma (pfp) of RF+RA patients with IgM-RF+ pEVs is shown (C). Pearson correlation
coefficient (r) and their p-value is shown. Mode particle size (D), protein content per particle (E) and amount of particles (F) from pEVs of these subdivided groups
(RF+RA patients with IgM-RF+ pEVs or IgM-RF− pEVs) are shown, measured by NTA and micro-BCA protein assay. Statistically significant differences were
determined by Mann–Whitney test, **p < 0.01.
although others reported that the protein content of EVs from
patients with RA is altered (25). The coagulation cascade in
serum can lead to massive EV release by thrombocytes as well
as by storage at −80◦C (26) and the observed differences could
be explained by the fact that platelet counts are increased in RA
patients (27).
Our study shows that IgM-RF is present in the pEVs
isolated after SEC separation in a subset of RF+RA patients,
and not in RF−RA patients nor healthy controls. The fact
that IgM-RF levels in the SEC isolated pEVs did not correlate
to levels detected in plasma makes it plausible that IgM-
RF is bound to pEVs. Furthermore, the presence of a lipid
bilayer (PKH26 staining) and binding to anti-CD63 confirmed
that these IgM-RF particles makes them true extracellular
vesicles.
ESR was enhanced in RF+RA patients compared to RF−RA
patients while other clinical parameters were not statistically
different. In this study we found that RF+RA patients with
detectable IgM-RF on their pEVs showed significantly higher
ESR compared to RF+RA patients without IgM-RF on their
pEVs and also CRP levels were statistically enhanced. CRP is
a sensitive index for RA disease activity and changes in CRP
can predict treatment response of patients (28). Interestingly, the
objective joint scores (TJC and SJC), which are considered the
most robust reflector of disease activity, did not differ between
these subgroups while the VAS (global assessment of disease
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FIGURE 5 | Antibody (IgG) binding to IgM-RF containing pEVs. SEC fraction 5 of 8 RA patients were incubated to anti-CD63 beads to specifically immobilize the EVs
to the beads. Thereafter, the beads were incubated with human IgG-PE and analyzed by FC. IgG binding to pEVs coupled to anti-CD63 magnetic beads was only
found in the RF+RA patients with IgM-RF+ pEVs (A). A representative FC plot is shown of a RF+RA patients with IgM-RF+ pEVs (black) and RF+RA patients with
IgM-RF− pEVs (gray) (B). (A,B) showed a IgG binding factor on pEVs. Next pEVs were stained by PKH26 and incubated with protein-L beads. The level of bound and
unbound PKH26-stained pEVs was measured by fluorometer (C). Reduced IgG-PE staining was observed on Protein L unbound IgM-RF+ pEVs bound to CD63
magnetic beads (black) as measured by FC (D). Statistically significant differences were determined by Mann–Whitney test, *p < 0.05.
TABLE 2 | Clinical data from RF+RA patients stratified in two groups based on presence of IgM-RF on their pEVs.
Rheumatoid arthritis disease status of RF+RA patients
IgM-RF− pEVs (n = 15) IgM-RF+ pEVs (n = 13)
Mean Count Mean Count P-value
Age in years 59 [26–85] 62 [31–84] 0.320
Gender male 2 (13.3%) 4 (30.8%)
female 13 (86.7%) 9 (69.2%)
DAS-28 score 3.47 [1.60–6.53] 4.90 [1.24–8.33] 0.033
IgM-RF - - -
+ 15 (100%) 13 (100%)
ESR (mm/hr) 18.0 [2–52] 46.3 [2–104] 0.007
CRP (mg/l) 8.0 [1–32] 24.0 [1–76] 0.016
VAS 28.4 [0–75] 67.9 [20–100] 0.0001
TJC 4.1 [0–13] 5.5 [0–22] 0.258
SJC 3.4 [0–9] 5.5 [0–16] 0.175
DMARDs use 13 (86.7%) 7 (53.8%)
Solumedrol use 8 (53.3%) 10 (76.9%)
Analgesics use 11 (73.3%) 11 (84.6%)
Biological use 2 (13.3%) 4 (30.8%)
Frontiers in Immunology | www.frontiersin.org 8 October 2018 | Volume 9 | Article 2388
Arntz et al. RA Severity and IgM-RF+ pEVs
FIGURE 6 | Clinical parameters related to IgM-RF containing pEVs. Clinical parameters were obtained at time of blood donation. RF+RA patients were dived in 2
subgroups based on the presence of IgM-RF+ pEVs and IgM-RF− pEVs in their circulation. TJC (A), SJC (B), DAS28 (C), VAS disease activity (D), CRP and ESR
levels (E,F) of these 2 subgroups are shown. Statistically significant differences were determined by Mann-Whitney test, *p < 0.05, **p < 0.01 and ***p < 0.001.
activity) was clearly increased. The VAS is a more subjective
index of patients general health of which pain and probably
other symptoms and manifestations of RA are reflected. The
disparity between global assessment of disease activity and the
number of tender and swollen joints is striking, however appears
to be in line with clinical literature in which (changes in)
global VAS are poorly explained (29). Additionally, the DAS28
was significantly enhanced in RA patients with IgM-RF on
their pEVs suggesting that DAS28, VAS, ESR, and CRP levels
reflect more the systemic disease component/phenotype of RA
in patients.
The enhanced levels of ESR, CRP and elevated VAS and
DAS28 we found in RA patients with IgM-RF+ pEVs may
suggest that these pEVs contributes to disease pathophysiology
in these patients. Autoantibodies like IgM-RF are very efficient
activators of the complement by a reaction with IgG (30). This
activation leads to the production of inflammatory cytokines in
synovial cells which can induce inflammation, cartilage damage
and bone erosion (1). In RA synovium Sato et al. have found
a more complement-dependency of inflammation with IgM-RF
and IgG3 than with other IgG subclasses suggested a dominant
role of IgG3 in RA (31), both IgM and IgG3 are the most
efficient of the human immunoglobulin (sub)classes in activating
complement. Saunderson et al. described the presence of IgG
on exosomes derived from B-cells (32). It is plausible that IgM-
RF is bound to IgG present on pEVs or that it recognizes IgG
autoantibodies that bind to antigens on EVs. Another possibility
is that the IgM-RF+ pEVs originate from autoreactive B-cells
and as B-cells play an important role in RA (18) there could be
a of changes in BCR repertoire, or enhanced B-cell activation
in this subgroup of RA patients with a more active disease. In
that case the IgM-RF+ pEVs could reflect changes in pre-B-
cell immunity and disease activity more rapidly than changes in
circulating levels of “free” IgM-RF, which reflects plasma activity.
The reported short circulation half-life of EVs in hours could
make the IgM-RF+ pEVs more responsive to changes in disease
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activity than free IgM-RF having a half-life of 5 days in the
circulation (33).
For future study, it would be interesting to measure the effect
of the B-cell depletion therapy by Rituximab on IgM-RF+ pEVs
and investigate whether changes in IgM-RF+ pEVs levels reflect
the drop in B-cells and the clinical response to this treatment.
In that case, measuring IgM-RF+ pEVs levels might be a way to
determine the efficacy of B-cell depletion therapy. Furthermore,
longitudinal studies may reveal whether we are dealing with a
unique subpopulation of RA patients or that the IgM-RF+ pEVs
merely reflects the disease state at the moment of blood sampling.
The IgM-RF+ pEVs levels could be a reflection of a combination
of inflammation and autoreactive B-cells activation.
It is plausible that Fc-receptors are activated by immune-
complexes formed by IgM-RF+ pEVs. Therefore, further
research is needed to investigate the added value of the presence
of EVs in the immune-complex induced Fc-receptor signaling.
To study their functional effect on immune cells requires the
use of pure IgM-RF+ pEVs and a recent described technique
would be suitable to separate IgM-RF+ pEVs from the total pEVs
population isolated from RA patients by advanced imaging flow
cytometry (34).
In conclusion, the present study shows for the first time that in
a subset of seropositive RA patients IgM-RF is present on pEVs
and this is related to higher disease activity. Our discovery sheds
new light on the disparity between global assessment of disease
activity and tender and swollen joints seemingly uncovering a
potential biological factor in the “subjective” measure of global
disease activity.
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